



## NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

**NOTICE IS HEREBY GIVEN** that an annual general and special meeting (the “**Meeting**”) of the shareholders of **Eviana Health Corporation** (the “**Company**”) will be held on **Friday, December 14, 2018**, at the hour of 11:00 a.m. (Vancouver time), at the offices of National Issuer Services Ltd. at Suite 760 – 777 Hornby Street, Vancouver, British Columbia V6Z 1S4 for the following purposes:

1. to receive and consider the audited consolidated financial statements of the Company for the years ended June 30, 2017, and June 30, 2018, and the respective reports of the auditors thereon;
2. to set the number of directors for the ensuing year at four;
3. to elect the directors of the Company;
4. to confirm the appointment by the board of directors of, and to appoint, the auditors of the Company and to authorize the directors to fix their remuneration;
5. to approve, ratify, and confirm all certain past acts and proceedings of the directors and officers of the Company for the year ending June 30, 2017; and
6. to transact such other business as may properly come before the Meeting or any adjournments or postponements thereof.

A shareholder wishing to be represented by proxy at the Meeting or any adjournment thereof must deposit his duly executed form of proxy with the Company's transfer agent and registrar, National Issuer Services Ltd., 760 - 777 Hornby Street, Vancouver, BC V6Z 1S4, not later than 11:00 a.m. (Vancouver time) on **Wednesday, December 12, 2018** or, if the Meeting is adjourned, not later than 48 hours, excluding Saturdays and holidays, preceding the time of such adjourned meeting.

Shareholders who are unable to attend the Meeting in person, are requested to date, complete, sign and return the enclosed form of proxy so that as large a representation as possible may be had at the Meeting.

The board of directors of the Company has by resolution fixed the close of business on Wednesday, November 14, 2018, as the record date, being the date for the determination of the registered holders of common shares of the Company entitled to receive notice of, and to vote at, the Meeting and any adjournment thereof.

The accompanying management information circular provides additional detailed information relating to the matters to be dealt with at the Meeting and is supplemental to, and expressly made a part of, this notice of annual general and special meeting. Additional information about the Company and its consolidated financial statements are also available on the Company's profile at [www.sedar.com](http://www.sedar.com).

**DATED** at Vancouver, British Columbia, the **14<sup>th</sup>** day of **November, 2018**.

**BY ORDER OF THE BOARD**

“*Sydney Au*” (*signed*)

Chief Financial Officer and Director



**MANAGEMENT INFORMATION CIRCULAR  
As at November 14, 2018**

**SOLICITATION OF PROXIES**

**THIS MANAGEMENT INFORMATION CIRCULAR IS FURNISHED IN CONNECTION WITH THE SOLICITATION BY THE MANAGEMENT OF EVIANA HEALTH CORPORATION** (the “**Company**”) of proxies to be used at the annual general and special meeting of shareholders of the Company to be held on Friday, December 14, 2018, at the offices of National Issuer Services Ltd. at Suite 760 – 777 Hornby Street, Vancouver, British Columbia V6Z 1S4 at the hour of 11:00 a.m. (Vancouver time), and at any adjournment or postponement thereof (the “**Meeting**”) for the purposes set out in the accompanying notice of meeting (the “**Notice**”). Although it is expected that the solicitation of proxies will be primarily by mail, proxies may also be solicited personally or by telephone, facsimile or other proxy solicitation services. In accordance with National Instrument 54-101 - *Communication with Beneficial Owners of Securities of a Reporting Issuer* (“**NI 54-101**”), arrangements have been made with brokerage houses and clearing agencies, custodians, nominees, fiduciaries or other intermediaries to send the Notice, this management information circular (“**Circular**”), the annual consolidated financial statements of the Company for the financial years ended June 30, 2017 and 2018 and related management's discussion and analysis and other meeting materials, if applicable (collectively the “**Meeting Materials**”) to the beneficial owners of the common shares of the Company (the “**Common Shares**”) held of record by such parties. The Company may reimburse such parties for reasonable fees and disbursements incurred by them in doing so. The costs of the solicitation of proxies will be borne by the Company. The Company may also retain, and pay a fee to, one or more professional proxy solicitation firms to solicit proxies from the shareholders of the Company in favour of the matters set forth in the Notice.

**APPOINTMENT AND REVOCATION OF PROXIES**

A holder of Common Shares who appears on the records maintained by the Company's registrar and transfer agent as a registered holder of Common Shares (each a “**Registered Shareholder**”) may vote in person at the Meeting or may appoint another person to represent such Registered Shareholder as proxy and to vote the Common Shares of such Registered Shareholder at the Meeting. In order to appoint another person as proxy, a Registered Shareholder must complete, execute and deliver the form of proxy accompanying this Circular, or another proper form of proxy, in the manner specified in the Notice.

The purpose of a form of proxy is to designate persons who will vote on the shareholder's behalf in accordance with the instructions given by the shareholder in the form of proxy. The persons named in the enclosed form of proxy are officers or directors of the Company. **A REGISTERED SHAREHOLDER DESIRING TO APPOINT SOME OTHER PERSON, WHO NEED NOT BE A SHAREHOLDER OF THE COMPANY, TO REPRESENT HIM OR HER AT THE MEETING MAY DO SO BY FILLING IN THE NAME OF SUCH PERSON IN THE BLANK SPACE PROVIDED IN THE FORM OF PROXY OR BY COMPLETING ANOTHER PROPER FORM OF PROXY.** A Registered Shareholder wishing to be represented by proxy at the Meeting or any adjournment thereof must, in all cases, deposit the completed form of proxy with the Company's transfer agent and registrar, National Issuer Services Ltd., 760 - 777 Hornby Street, Vancouver, BC V6Z 1S4, (the “**Transfer**

**Agent**”), not later than 11:00 a.m. (Vancouver time) on **December, 12, 2018**, or, if the Meeting is adjourned, not later than 48 hours, excluding Saturdays, Sundays and holidays, preceding the time of such adjourned Meeting at which the form of proxy is to be used. A form of proxy should be executed by the Registered Shareholder or his or her attorney duly authorized in writing or, if the Registered Shareholder is a corporation, by an officer or attorney thereof duly authorized.

A Registered Shareholder attending the Meeting has the right to vote in person and, if he or she does so, his or her form of proxy is nullified with respect to the matters such person votes upon at the Meeting and any subsequent matters thereafter to be voted upon at the Meeting or any adjournment thereof.

A Registered Shareholder who has given a form of proxy may revoke the form of proxy at any time prior to using it by: (a) depositing an instrument in writing, including another completed form of proxy, executed by such Registered Shareholder or by his or her attorney authorized in writing or by electronic signature or, if the Registered Shareholder is a corporation, by an authorized officer or attorney thereof, at, or by transmitting by telephone or electronic means, a revocation signed, by electronic signature, to (i) the office of National Issuer Services Ltd., located at 760 - 777 Hornby Street, Vancouver, BC V6Z 1S4, at any time prior to 5:00 p.m. (Vancouver time) on the last business day preceding the day of the Meeting or any adjournment thereof or (ii) with the Chairman of the Meeting on the day of the Meeting or any adjournment thereof; or (b) any other manner permitted by law.

### **EXERCISE OF DISCRETION BY PROXIES**

The Common Shares represented by proxies in favour of management nominees will be voted or withheld from voting in accordance with the instructions of the Registered Shareholder on any ballot that may be called for and, if a Registered Shareholder specifies a choice with respect to any matter to be acted upon at the meeting, the Common Shares represented by the proxy shall be voted accordingly. Where no choice is specified, the proxy will confer discretionary authority and will be voted for the election of directors, for the appointment of auditors and the authorization of the directors to fix their remuneration, and for each item of special business, if applicable, as stated elsewhere in this Circular.

The enclosed form of proxy also confers discretionary authority upon the persons named therein to vote with respect to any amendments or variations to the matters identified in the Notice and with respect to other matters which may properly come before the Meeting in such manner as such nominee in his judgment may determine. At the time of printing this Circular, the management of the Company knows of no such amendments, variations or other matters to come before the Meeting.

### **ADVICE TO NON-REGISTERED SHAREHOLDERS**

**The information set forth in this section is of significant importance to many shareholders of the Company, as a substantial number of shareholders of the Company do not hold Common Shares in their own name.** Only Registered Shareholders or the persons they appoint as their proxies are permitted to attend and vote at the Meeting and only forms of proxy deposited by Registered Shareholders will be recognized and acted upon at the Meeting. Common Shares beneficially owned by a beneficial holder of Common Shares who does not appear on the records maintained by the registrar and transfer agent of the Company as a registered holder of Common Shares (each a “**Non-Registered Holder**”) are registered either: (i) in the name of an intermediary (an “**Intermediary**”) with whom the Non-Registered Holder deals in respect of the Common Shares (Intermediaries include, among others, banks, trust companies, securities dealers or brokers and trustees or administrators of self-administered RRSPs, RRIFs, RESPs and similar plans); or (ii) in the name of a clearing agency (such as CDS Clearing and Depository Services Inc.) (each a “**Clearing Agency**”) of which the Intermediary is a participant. Accordingly, such Intermediaries and Clearing Agencies would be the Registered Shareholders and would appear as such on

the list maintained by the Transfer Agent. Non-Registered Holders do not appear on the list of the Registered Shareholders maintained by the Transfer Agent.

### ***Distribution of Meeting Materials to Non-Registered Holders***

In accordance with the requirements of NI 54-101, the Company has distributed copies of the Meeting Materials to the Clearing Agencies and Intermediaries for onward distribution to Non-Registered Holders as well as directly to NOBOs (as defined below).

Non-Registered Holders fall into two categories - those who object to their identity being known to the issuers of securities which they own (“**OBOs**”) and those who do not object to their identity being made known to the issuers of the securities which they own (“**NOBOs**”). Subject to the provisions of NI 54-101, issuers may request and obtain a list of their NOBOs from Intermediaries directly or via their transfer agent and may obtain and use the NOBO list for the distribution of proxy-related materials to such NOBOs. If you are a NOBO and the Company or its agent has sent the Meeting Materials directly to you, your name, address and information about your holdings of Common Shares have been obtained in accordance with applicable securities regulatory requirements from the Intermediary holding the Common Shares on your behalf.

The Company's OBOs can expect to be contacted by their Intermediary. The Company does not intend to pay for Intermediaries to deliver the Meeting Materials to OBOs and it is the responsibility of such Intermediaries to ensure delivery of the Meeting Materials to their OBOs.

### ***Voting by Non-Registered Holders***

The Common Shares held by Non-Registered Holders can only be voted or withheld from voting at the direction of the Non-Registered Holder. Without specific instructions, Intermediaries or Clearing Agencies are prohibited from voting Common Shares on behalf of Non-Registered Holders. Therefore, each Non-Registered Holder should ensure that voting instructions are communicated to the appropriate person well in advance of the Meeting.

The various Intermediaries have their own mailing procedures and provide their own return instructions to Non-Registered Holders, which should be carefully followed by Non-Registered Holders in order to ensure that their Common Shares are voted at the Meeting.

Non-Registered Holders will receive either a voting instruction form or, less frequently, a form of proxy. The purpose of these forms is to permit Non-Registered Holders to direct the voting of the Common Shares they beneficially own. Non-Registered Holders should follow the procedures set out below, depending on which type of form they receive.

A. *Voting Instruction Form.* In most cases, a Non-Registered Holder will receive, as part of the Meeting Materials, a voting instruction form (a “**VIF**”). If the Non-Registered Holder does not wish to attend and vote at the Meeting in person (or have another person attend and vote on the Non-Registered Holder's behalf), the VIF must be completed, signed and returned in accordance with the directions on the form.

or,

B. *Form of Proxy.* Less frequently, a Non-Registered Holder will receive, as part of the Meeting Materials, a form of proxy that has already been signed by the Intermediary (typically by a facsimile, stamped signature) which is restricted as to the number of Common Shares beneficially owned by the Non-Registered Holder but which is otherwise not completed. If the Non-Registered Holder does not wish to attend and vote at the Meeting in person (or have another person attend and vote on the Non-

Registered Holder's behalf), the Non-Registered Holder must complete and sign the form of proxy and in accordance with the directions on the form.

***Voting by Non-Registered Holders at the Meeting***

Although a Non-Registered Holder may not be recognized directly at the Meeting for the purposes of voting Common Shares registered in the name of an Intermediary or a Clearing Agency, a Non-Registered Holder may attend the Meeting as proxyholder for the Registered Shareholder who holds Common Shares beneficially owned by such Non-Registered Holder and vote such Common Shares as a proxyholder. A Non-Registered Holder who wishes to attend the Meeting and to vote their Common Shares as proxyholder for the Registered Shareholder who holds Common Shares beneficially owned by such Non-Registered Holder, should (a) if they received a VIF, follow the directions indicated on the VIF; or (b) if they received a form of proxy strike out the names of the persons named in the form of proxy and insert the Non-Registered Holder's or its nominees name in the blank space provided. Non-Registered Holders should carefully follow the instructions of their Intermediaries, including those instructions regarding when and where the VIF or the form of proxy is to be delivered.

All references to shareholders in the Meeting Materials are to Registered Shareholders as set forth on the list of registered shareholders of the Company as maintained by the Transfer Agent, unless specifically stated otherwise.

**VOTING SECURITIES AND PRINCIPAL HOLDERS OF VOTING SECURITIES**

The authorized share capital of the Company consists of an unlimited number of Common Shares without par value, and an unlimited number of preferred shares without par value. As of November 14, 2018 (the “**Record Date**”), there were a total of 23,899,849 Common Shares and no preferred shares issued and outstanding. Each Common Share outstanding on the Record Date carries the right to one vote at the Meeting.

Only Registered Shareholders as of the Record Date are entitled to receive notice of, and to attend and vote at, the Meeting or any adjournment or postponement of the Meeting. On a show of hands, every Registered Shareholder and proxy holder will have one vote and, on a poll, every Registered Shareholder present in person or represented by proxy will have one vote for each Common Share held.

To the knowledge of the Company's directors and executive officers, as of the date hereof, no person or company beneficially owns, directly or indirectly, or exercises control or direction over, Common Shares carrying more than 10% of the voting rights attached to the outstanding Common Shares, other than as set forth below:

<b>Name<sup>(1)</sup></b>	<b>Number of Common Shares</b>	<b>Percentage of Issued and Outstanding Common Shares</b>
Avram Adizes	5,290,374 <sup>(2)</sup>	22.14%
Olivier Benloulou	2,934,200	12.28%

*Notes:*

- (1) *The above information is based upon information supplied by the Transfer Agent, the Company's management, and from the SEDI database.*
- (2) *3,450,000 of such Common Shares are held by A+ Crowd Disruptive Innovation Inc., a corporation controlled by Dr. Adizes, and 50,000 of such Common Shares are held by Eviana Inc.*

## **INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED ON**

No director or executive officer of the Company who was a director or executive officer at any time since the beginning of the Company's last financial year, or any associate or affiliates of any such directors or officers, has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Meeting.

## **PARTICULARS OF MATTERS TO BE ACTED UPON**

To the knowledge of the board of directors of the Company (the “**Board**”), the matters to be brought before the Meeting are those matters set forth in the accompanying Notice.

### **1. PRESENTATION OF FINANCIAL STATEMENTS**

The audited financial statements of the Company for the year ended June 30, 2017, and the audited consolidated financial statements of the Company for the year ended June 30, 2018 and the respective reports of the auditors thereon will be placed before the shareholders at the Meeting. No vote will be taken on the financial statements. The consolidated financial statements and additional information concerning the Company are available under the Company's profile at [www.sedar.com](http://www.sedar.com).

### **2. SETTING NUMBER OF DIRECTORS**

Management proposes to nominate the persons named under the heading “Election of Directors” below for election as directors of the Company. Each director elected will hold office until the next annual general meeting or until his/her successor is duly elected or appointed, unless his/her office is earlier vacated in accordance with the Articles of the Company or he/she becomes disqualified to act as a director.

It is proposed to set the number of directors at four (4). This requires the approval of the shareholders of the Company by an ordinary resolution, which approval will be sought at the Meeting.

**UNLESS THE SHAREHOLDER DIRECTS THAT HIS OR HER COMMON SHARES ARE TO BE WITHHELD FROM VOTING IN CONNECTION WITH THE SETTING OF THE NUMBER OF DIRECTORS, THE PERSONS NAMED IN THE ENCLOSED FORM OF PROXY INTEND TO VOTE FOR THE NUMBER OF DIRECTORS OF THE COMPANY TO BE SET AT FOUR (4).**

### **3. ELECTION OF DIRECTORS**

The Board currently consists of five directors. The Board has determined that the number of directors to be nominated at the Meeting be four, as Michael Galloro has determined not stand for re-election. The following table states the names of the persons nominated by management for election as directors, any offices with the Company currently held by them, their principal occupations or employment, the period or periods of service as directors of the Company and the approximate number of voting securities of the Company beneficially owned, directly or indirectly, or over which control or direction is exercised as of the date hereof.

Name, province or state and country of residence and position, if any, held in the Company	Principal Occupation for Five Preceding Years	Served as Director of the Company since:	Number of Common Shares beneficially owned, directly or indirectly, or controlled or directed at present <sup>(1)</sup>	Percentage of Voting Shares Owned or Controlled
Dr. Avram Adizes  Ontario, Canada  Chief Executive Officer and Chairman of the Board	Engineer  Chief Executive Officer and Chairman of the Company (Aug 2017-present); founder of Intiva Plus doo	August 31, 2017	5,290,374 <sup>(2)</sup>	22.14%
Sydney Au <sup>(3)</sup>  Vancouver, Canada  Chief Financial Officer and Director	Business Executive  President and Chairman of Evitrade Health Systems Corp. (April 2012-present).	June 19, 2013	220,290	0.92%
Prof. Ljiljana Vujotic <sup>(3)</sup>  Ontario, Canada  Director	Scientist  Head of the Pediatric Neurosurgery Department, Clinical Center of the Serbia Neurosurgery Division in Belgrade, Serbia (2004-present)	August 31, 2017	1,500,000	6.28%
Paolo De Luca <sup>(3)</sup>  Ontario, Canada  Director	Chartered Professional Accountant, Chartered Financial Analyst  Chief Financial Officer of Organigram Holdings Inc. (Dec. 2017-present); Chief Financial Officer of Meridian LNG, an investment of West Face Capital Inc. (Dec. 2013-Dec. 2017); Chief Financial Officer of Potash Ridge Corporation (Sept. 2011-July 2012).	October 2, 2018	Nil	Nil

*Notes:*

- (1) *The information as to voting securities beneficially owned, controlled or directed, not being within the knowledge of the Company, has been furnished by the respective nominees individually.*
- (2) *3,450,000 of such Common Shares are held by A+ Crowd Disruptive Innovation Inc., a corporation controlled by Dr. Adizes, and 50,000 of such Common Shares are held by Eviana Inc.*
- (3) *Member of the Audit Committee. It is proposed that Paolo De Luca will be appointed as the third member of the Audit Committee.*

The term of office of each director will be from the date of the meeting at which he is elected until the next annual general meeting, or until his successor is elected or appointed.

**PROXIES RECEIVED IN FAVOUR OF MANAGEMENT WILL BE VOTED FOR THE ELECTION OF THE ABOVE-NAMED NOMINEES, UNLESS THE SHAREHOLDER HAS SPECIFIED IN THE PROXY THAT HIS OR HER SHARES ARE TO BE WITHHELD FROM VOTING IN RESPECT THEREOF. MANAGEMENT HAS NO REASON TO BELIEVE THAT ANY OF THE NOMINEES WILL BE UNABLE TO SERVE AS A DIRECTOR BUT, IF A NOMINEE IS FOR ANY REASON UNAVAILABLE TO SERVE AS A DIRECTOR, PROXIES IN FAVOUR OF MANAGEMENT WILL BE VOTED IN FAVOUR OF THE REMAINING NOMINEES AND MAY BE VOTED FOR A SUBSTITUTE NOMINEE UNLESS THE SHAREHOLDER HAS SPECIFIED IN THE PROXY THAT HIS OR HER SHARES ARE TO BE WITHHELD FROM VOTING IN RESPECT OF THE ELECTION OF DIRECTORS.**

***Corporate Cease Trade Orders or Bankruptcies***

No proposed director, within 10 years before the date of this Circular, has been a director, chief executive officer or chief financial officer of any company that:

- (a) was subject to: (i) a cease trade order; (ii) an order similar to a cease trade order; or (iii) an order that denied the relevant company access to any exemption under securities legislation, that was in effect for a period of more than 30 consecutive days (collectively, an “**Order**”) and that was issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer; or
- (b) was subject to an Order that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer.

No proposed director, within 10 years before the date of this Circular, has been a director or executive officer of any company that, while the proposed director was acting in that capacity, or within a year of the proposed director ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

#### ***Personal Bankruptcies***

None of the directors of the Company have, within the 10 years before the date of this Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of such person.

#### ***Penalties and Sanctions***

None of the directors of the Company have been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority or been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.

#### **4. CONFIRMATION AND APPOINTMENT OF AUDITORS**

BDO Canada LLP (“**BDO**”) was appointed as the auditor of the Company effective October 23, 2018, replacing the Company’s former auditor, Adam Sung Kim Ltd. (“**ASK**”), that resigned effective October 23, 2018, at the request of the Company. The Company’s determination to change the auditor was not as a result of any “reportable event” as such term is defined in National Instrument 51-102 – *Continuous Disclosure Obligations* (“**NI 51-102**”). The resignation of ASK and appointment of BDO was considered and, upon recommendation of the audit committee of the Board, approved by the Board. In connection with this change in auditor, the change of auditor “reporting package”, as such term is defined in NI 51-102, was filed on System for Electronic Document Analysis and Retrieval (“**SEDAR**”) at [www.sedar.com](http://www.sedar.com) and is attached as Appendix “B” to this Circular. The reporting package in Appendix “B” consists of (i) Notice of Change of Auditor; (ii) Letter from ASK; and (iii) Letter from BDO.

Shareholders are being asked to confirm the actions of the Board and to appoint BDO as auditors of the Company to hold office until the next annual general meeting of shareholders and to authorize the Board to fix the remuneration of the auditors.

**UNLESS THE SHAREHOLDER DIRECTS THAT HIS OR HER COMMON SHARES ARE TO BE WITHHELD FROM VOTING IN CONNECTION WITH THE CONFIRMATION AND**

**APPOINTMENT OF AUDITORS, THE PERSONS NAMED IN THE ENCLOSED FORM OF PROXY INTEND TO VOTE FOR THE APPOINTMENT OF BDO AS THE AUDITORS OF THE COMPANY UNTIL THE NEXT ANNUAL GENERAL MEETING OF SHAREHOLDERS AND TO AUTHORIZE THE DIRECTORS TO FIX THEIR REMUNERATION.**

## **5. RATIFICATION OF PAST ACTS**

The Company had not previously held its annual general meeting for the fiscal year ending June 30, 2017 and wishes to have shareholders approve, ratify, and confirm all certain past acts and proceedings of the directors and officers of the Company for the fiscal year ending June 30, 2017 as disclosed in this Circular and otherwise disclosed by the Company at its SEDAR profile at [www.sedar.com](http://www.sedar.com).

**UNLESS THE SHAREHOLDER DIRECTS THAT HIS OR HER COMMON SHARES ARE TO BE VOTED AGAINST THE RATIFICATION OF PAST ACTS, THE PERSONS NAMED IN THE ENCLOSED FORM OF PROXY INTEND TO VOTE FOR THE RATIFICATION OF PAST ACTS.**

### **STATEMENT OF EXECUTIVE COMPENSATION**

#### **Named Executive Officers**

For the purposes of this Circular, a “**Named Executive Officer**” of the Company means each of the following individuals:

- (a) a Chief Executive Officer of the Company;
- (b) a Chief Financial Officer of the Company;
- (c) each of the Company's three most highly compensated executive officers, or the three most highly compensated individuals acting in a similar capacity, other than the Chief Executive Officer and the Chief Financial Officer, at the end of the most recently completed financial year whose total compensation was, individually, more than \$150,000, as determined in accordance with subsection 1.3(5) of Form 51-102F6V, for that financial year; and
- (d) each individual who would be an Named Executive Officer under paragraph (c) above but for the fact that the individual was neither an executive officer of the Company, nor acting in a similar capacity, at the end of that financial year.

The Named Executive Officers of the Company during the financial year ended June 30, 2018 were Avram Adizes, Chief Executive Officer and Chairman, Sydney Au, Chief Financial Officer and Director, and Daniel Bloch (former President, Secretary and Director).

#### **Summary Compensation Table**

The following table provides a summary of compensation paid, directly or indirectly, for each of the two most recently completed financial years to the Named Executive Officers and the directors of the Company:

TABLE OF COMPENSATION EXCLUDING COMPENSATION SECURITIES <sup>(1)</sup>							
Name and position	Year Ended June 30	Salary, consulting fee, retainer or commission (\$)	Bonus (\$)	Committee or meeting fees (\$)	Value of perquisites (\$)	Value of all other compensation (\$)	Total compensation (\$)
Dr. Avram Adizes Chief Executive Officer and Chairman	2018 2017	100,000 <sup>(2)</sup> N/A	Nil N/A	Nil N/A	Nil N/A	Nil N/A	100,000 N/A
Sydney Au Chief Financial Officer and Director	2018 2017	50,000 <sup>(3)</sup> Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil	50,000 Nil
Prof. Ljiljana Vujotic Director	2018 2017	100,000 <sup>(4)</sup> N/A	Nil N/A	Nil N/A	Nil N/A	Nil N/A	100,000 N/A
Paolo De Luca <sup>(5)</sup> Director	2018 2017	N/A N/A	N/A N/A	N/A N/A	N/A N/A	N/A N/A	N/A N/A
Michael Galloro Director	2018 2017	Nil <sup>(6)</sup> N/A <sup>(6)</sup>	Nil N/A	Nil N/A	Nil N/A	Nil N/A	Nil N/A
Daniel Bloch <sup>(7)</sup> Former President, Secretary and Director	2018 2017	250,000 <sup>(8)</sup> N/A	Nil N/A	Nil N/A	Nil N/A	Nil N/A	250,000 N/A

Notes:

- (1) This table does not include any amount paid as reimbursement for expenses.
- (2) Based on annual base compensation of \$120,000, pro-rated for ten (10) months during the financial year ended June 30, 2018, billed by A+ Crowd Disruptive Innovation Inc., a company of which Dr. Adizes is the Principal.
- (3) Based on annual base compensation of \$60,000, pro-rated for ten (10) months during the financial year ended June 30, 2018, billed by 0918368 B.C. Limited, a company of which Mr. Au is the Principal.
- (4) Based on annual base compensation of \$120,000, pro-rated for ten (10) months during the financial year ended June 30, 2018.
- (5) Paolo De Luca was appointed to the Board effective October 2, 2018.
- (6) Consulting fees of \$106,844 (2017 - \$20,400) were paid to ALOE Finance Inc., a company of which Michael Galloro is the Principal.
- (7) Daniel Bloch resigned as a director and officer of the Company effective February 28, 2018.
- (8) Compensation received as part of a resignation settlement.

### Stock Options and Other Compensation Securities

The following table provides a summary of all compensation securities granted or issued to each Named Executive Officer and to each director of the Company during the most recently completed financial year of the Company for services provided or to be provided, directly or indirectly, to the Company or any of its subsidiaries:

COMPENSATION SECURITIES							
Name and position	Type of compensation security	Number of compensation securities, number of underlying securities, and percentage of class <sup>(1)</sup>	Date of issue or grant	Issue, conversation or exercise price (\$)	Closing price of security or underlying security on date of grant <sup>(2)</sup> (\$)	Closing price of security or underlying security at year end (\$)	Expiry Date
Dr. Avram Adizes <sup>(3)</sup> Chief Executive Officer, Chairman	Stock Options	250,000 Stock Options exercisable for 250,000 Common Shares representing 1.03% of the outstanding number of Common Shares	August 31, 2017	\$1.00	N/A	\$1.10	August 31, 2022
		150,000 Stock Options exercisable for 150,000 Common Shares representing 0.62% of the outstanding number of Common Shares	September 11, 2017	\$1.00	N/A	\$1.10	August 31, 2022
		60,000 Stock Options exercisable for 60,000 Common Shares representing 0.25% of the outstanding number of Common Shares	February 15, 2018	\$1.61	\$1.61	\$1.10	February 15, 2023
Sydney Au <sup>(4)</sup> Chief Financial Officer	Stock Options	250,000 Stock Options exercisable for 60,000 Common Shares representing 1.03% of the outstanding number of Common Shares	August 31, 2017	\$1.00	N/A	\$1.10	August 31, 2022
		60,000 Stock Options exercisable for 60,000 Common Shares representing 0.25% of the outstanding number of Common Shares	February 15, 2018	\$1.61	\$1.61	\$1.10	February 15, 2023
Michael Galloro <sup>(5)</sup>	Stock Options	250,000 Stock Options exercisable for 250,000 Common Shares representing 1.03% of the outstanding number of Common Shares	August 31, 2017	\$1.00	N/A	\$1.10	August 31, 2022
		60,000 Stock Options exercisable for 60,000 Common Shares representing 0.25% of the outstanding number of Common Shares	February 15, 2018	\$1.61	\$1.61	\$1.10	February 15, 2023
Daniel Bloch <sup>(6)(7)</sup> Director	Stock Options	250,000 Stock Options exercisable for 250,000 Common Shares representing 1.03% of the outstanding number of Common Shares	August 31, 2017	\$1.00	N/A	\$1.10	August 31, 2022

COMPENSATION SECURITIES							
Name and position	Type of compensation security	Number of compensation securities, number of underlying securities, and percentage of class <sup>(1)</sup>	Date of issue or grant	Issue, conversation or exercise price (\$)	Closing price of security or underlying security on date of grant <sup>(2)</sup> (\$)	Closing price of security or underlying security at year end (\$)	Expiry Date
Prof. Ljiljana Vujotic <sup>(8)</sup> Director	Stock Options	235,000 Stock Options exercisable for 235,000 Common Shares representing 0.97% of the outstanding number of Common Shares	February 15, 2018	\$1.61	\$1.61	\$1.10	February 15, 2023

Notes:

- (1) The percentage of class is calculated on a partially diluted basis as at June 30, 2018.
- (2) The Common Shares commenced trading on the Canadian Securities exchange on September 12, 2017.
- (3) As at June 30, 2018, Dr. Adizes held 460,000 stock options exercisable to purchase 460,000 Common Shares.
- (4) As at June 30, 2018, Mr. Au held 310,000 stock options exercisable to purchase 310,000 Common Shares.
- (5) As at June 30, 2018, Mr. Galloro held 310,000 stock options exercisable to purchase 310,000 Common Shares.
- (6) As at June 30, 2018, Mr. Bloch held Nil stock options exercisable to purchase Nil Common Shares.
- (7) Mr. Bloch resigned as an officer and director of the Company effective February 28, 2018.
- (8) As at June 30, 2018, Prof. Vujotic held 235,000 stock options exercisable to purchase 235,000 Common Shares.

The table below sets out each exercise by a director or Named Executive Officer of the Company of compensation securities during the most recently completed financial year:

EXERCISE OF COMPENSATION SECURITIES BY DIRECTORS AND NAMED EXECUTIVE OFFICERS							
Name and position	Type of compensation security	Number of underlying securities exercised	Exercise price per security (\$)	Date of exercise	Closing price per security on date of exercise <sup>(2)</sup> (\$)	Difference between exercise price and closing price on date of exercise (\$)	Total value on exercise date (\$)
Daniel Bloch <sup>(1)</sup> Director	Stock Options	250,000	\$1.00	February 26, 2018	\$1.70	\$0.70	175,000

Notes:

- (1) Mr. Bloch resigned as an officer and director of the Company effective February 28, 2018.

### Stock Option Plan and Other Incentive Plans

The Company has adopted the Stock Option Plan whereby a maximum of 10% of the issued and outstanding Common Shares, from time to time, may be reserved for issuance pursuant to the exercise of options.

Options may be granted under the Stock Option Plan to (i) directors, senior officers, management company employees, employees or consultants of the Company or an affiliate of the Company, as determined by the Board. The Board may from time to time determine the eligible persons to whom Options shall be granted, the number of Common Shares to be made subject to and the expiry date of each Option granted to each eligible person, and the other terms of each Option granted.

Any Common Shares subject to an option which for any reason is cancelled or terminated prior to exercise will be available for a subsequent grant under the Stock Option Plan. The price per share at which any Common Share which is the subject of an Option may be purchased shall be determined by the Board at the time the Option is granted, provided that the exercise price shall be not less than \$0.05 or the minimum price permitted on the stock exchange on which the Common Shares trade as at the date of grant.

The options are non-assignable and non-transferable. Options granted under the Stock Option Plan can only be exercised by the optionee as long as the optionee remains an eligible optionee pursuant to the Stock Option Plan or within 90 days (or such longer period not exceeding 12 months as determined from time to time by the Board) after ceasing to be an eligible optionee, or, if the optionee dies, within one year from the date of the optionee's death.

Subject to applicable securities law and the rules and policies of the stock exchange upon which the Common Shares trade, the Board may from time to time amend or revise the terms of the Stock Option Plan or may terminate the Stock Option Plan at any time. The Stock Option Plan does not contain any provision for financial assistance by the Company in respect of options granted under the Stock Option Plan.

The Stock Option Plan was adopted by the Board on August 31, 2017.

### **Employment, Consulting and Management Agreements**

Pursuant to a consulting agreement dated September 12, 2017 (the “**Adizes Agreement**”), the Company engaged A+ Crowd Disruptive Innovation Inc. (“**A+ Crowd**”) to provide executive management, corporate leadership, corporate finance, human resources, and business development services and engaged the services of Dr. Avram Adizes, the Principal of A+ Crowd, to act in the role of CEO of the Company. The initial term of the Adizes Agreement is one (1) year from execution and will automatically renew for additional one (1) year terms unless earlier terminated by either party. Pursuant to the Adizes Agreement, A+ Crowd is entitled to an annual base compensation of \$120,000, plus cash bonus and Stock Options at the discretion of the Board. Pursuant to the Adizes Agreement, upon termination of the agreement due to (i) a material breach by the Company not remedied within thirty (30) days, (ii) a material reduction by the Company in compensation or services to be provided, (iii) a change of control, (iv) termination by the Company other than for cause, or if the Company elects not to renew the Adizes Agreement for an additional term, the Company shall pay a settlement amount equal to two years of base compensation plus average bonus paid over last two years.

Pursuant to a consulting agreement dated September 12, 2017 (the “**Au Agreement**”), the Company engaged 0918368 B.C. Limited (“**Au Co**”) to provide executive financial and organizational management, statutory financial reporting, tax compliance, and legal compliance services and engaged the services of Sydney Au, the Principal of Au Co, to act in the role of CFO of the Company. The initial term of the Au Agreement is one (1) year from execution and will automatically renew for additional one (1) year terms unless earlier terminated by either party. Pursuant to the Au Agreement, Au Co is entitled to an annual base compensation of \$60,000, plus cash bonus and Stock Options at the discretion of the Board. Pursuant to the Au Agreement, upon termination of the agreement due to (i) a material breach by the Company not remedied within thirty (30) days, (ii) a material reduction by the Company in compensation or services to be provided, (iii) a change of control, (iv) termination by the Company other than for cause, or if the Company elects not to renew the Au Agreement for an additional term, the Company shall pay a settlement amount equal to two years of base compensation plus average bonus paid over last two years.

Pursuant to a consulting agreement dated September 12, 2017 (the “**Vujotic Agreement**”), the Company engaged Professor Ljiljana Vujotic to provide certain medical and scientific services to the Company. The

initial term of the Vujotic Agreement is one (1) year from execution and will automatically renew for additional one (1) year terms unless earlier terminated by either party. Pursuant to the Vujotic Agreement, Prof. Vujotic is entitled to an annual base compensation of \$120,000, plus cash bonus and Stock Options at the discretion of the Board. Pursuant to the Vujotic Agreement, upon termination of the agreement due to (i) a material breach by the Company not remedied within thirty (30) days, (ii) a material reduction by the Company in compensation or services to be provided, (iii) a change of control, (iv) termination by the Company other than for cause, or if the Company elects not to renew the Vujotic Agreement for an additional term, the Company shall pay a settlement amount equal to two years of base compensation plus average bonus paid over last two years.

Pursuant to an agreement dated April 5, 2018, the Company engaged ALOE Finance Inc. (the “**ALOE Agreement**”), a company of which Michael Galloro is the Principal, to provide certain financial and book-keeping services. Pursuant to the ALOE Agreement, ALOE Finance Inc. is entitled to monthly compensation of \$5,000, plus additional fees are charge for quarterly and year-end financial reporting based on time expended by ALOE Finance Inc.

### **Oversight and Description of Director and Named Executive Officer Compensation**

Decisions regarding the compensation of Named Executive Officers and directors are made by the Board. When determining the compensation of the Named Executive Officers and directors, the Board considers the resources of the Company and the objectives of: (i) recruiting and retaining the executives and directors critical to the success of the Company and the enhancement of shareholder value; (ii) providing fair and competitive compensation; (iii) balancing the interests of management and shareholders of the Company; and (iv) rewarding performance, both on an individual basis and with respect to the business in general. In order to achieve these objectives, the compensation paid to the Named Executive Officers consists of the following two components:

- (a) base fee or salary; and
- (b) long-term incentive in the form of stock options.

#### Base Fee or Salary

The base fee or salary of each particular Named Executive Officer is determined by an assessment by the Board of such executive's performance, a consideration of competitive compensation levels in companies similar to the Company and a review of the performance of the Company as a whole and the role such executive officer played in such corporate performance.

#### Long-Term Incentive

The Company provides a long-term incentive by granting options to executive officers and directors under the Stock Option Plan. The objective of granting options is to encourage executives to acquire an ownership interest in the Company over a period of time, which acts as a financial incentive for such executive to consider the long-term interests of the Company and its shareholders.

#### Option Based Awards

The Board reviews the performance of the Company's management, directors and advisors from time to time, and recommends option-based awards and other compensation awards or adjustments. These decisions take into consideration corporate and individual performance and industry standards. Previous grants of option-based awards are also taken into consideration in making this determination. The

experience of the Board members who are also involved as management of, or Board members or advisors to, other companies also informs decisions concerning compensation.

### **Pension and Retirement Plans and Payments made upon Termination of Employment**

The Company does not have any pension or retirement plan which is applicable to the Named Executive Officers or directors.

### **SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLAN**

The following table sets forth information with respect to all compensation plans of the Company under which equity securities are authorized for issuance as of June 30, 2018:

#### **Equity Compensation Plan Information**

<b>Plan Category</b>	<b>Number of securities to be issued upon exercise of outstanding options, warrants and rights (#)</b>	<b>Weighted-average exercise price of outstanding options, warrants and rights (\$)</b>	<b>Number of securities remaining available for future issuance under equity compensation plans (#)</b>
Equity compensation plans approved by securityholders	Nil	N/A	N/A
Equity compensation plans not approved by securityholders	1,750,000	1.26	639,984
<b>Total</b>	<b>1,750,000</b>	<b>1.26</b>	<b>639,984</b>

*Note:*

(1) *The Stock Option Plan is a “rolling” stock option plan whereby the maximum number of Common Shares that may be reserved for issue pursuant to the Stock Option Plan will not exceed 10% of the outstanding Common Shares at the time of the stock option grant. As at the date of this Circular, 2,389,984 stock options may be issued under the Stock Option Plan, 1,750,000 stock options are outstanding and an additional 639,984 Common Shares are reserved for issue and remain available for future issue under the Stock Option Plan.*

### **INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS**

No director, executive officer or principal shareholder of the Company, or associate or affiliate of any of the foregoing, has had any material interest, direct or indirect, in any transaction since July 1, 2017 or in any proposed transaction that has materially affected or will materially affect the Company.

### **INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS**

No director or officer of the Company or person who acted in such capacity in the last financial year of the Company, or any other individual who at any time during the most recently completed financial year of the Company was a director of the Company or any associate of the Company, is indebted to the Company, nor is any indebtedness of any such person to another entity the subject of a guarantee, support agreement, letter of credit or other similar arrangement or understanding provided by the Company.

### **AUDIT COMMITTEE INFORMATION REQUIRED IN THE INFORMATION CIRCULAR OF A VENTURE ISSUER**

Canadian Securities Administrators' National Instrument 52-110 – *Audit Committees* (“**NI 52-110**”) requires that certain information regarding the Audit Committee of a “venture issuer” (as that term is defined in NI 52-110) be included in an AIF or the management information circular sent to shareholders

in connection with the issuer's annual meeting. The Company is a “venture issuer” for the purposes of NI 52-110.

### **Audit Committee Charter**

The full text of the charter of the Company's Audit Committee is attached hereto as appendix A.

### **Composition of the Audit Committee**

The Audit Committee members are currently Michael Galloro, Sydney Au and Ljiljana Vujotic, each of whom is a director of the Company and financially literate, and of which Mr. Galloro is independent within the meaning set out in NI 52-110. Following the Meeting, it is expected that Paolo De Luca will be appointed to the Audit Committee to replace Mr. Galloro. Mr. De Luca is financially literate and independent within the meaning set out in NI 52-110. Neither Prof. Vujotic nor Mr. De Luca are executive officers, employees or control persons of the Company.

### **Relevant Education and Experience**

The following is a description of the education and experience of each member of the Audit Committee that is relevant to the performance of his responsibilities as an Audit Committee member and, in particular, any education or experience that would provide the member with:

1. an understanding of the accounting principles used by the Company to prepare its financial statements;
2. the ability to assess the general application of such accounting principles in connection with the accounting for estimates, accruals and reserves;
3. experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company's financial statements, or experience actively supervising one or more persons engaged in such activities; and
4. an understanding of internal controls and procedures for financial reporting.

***Sydney Au, Chief Financial Officer and Director*** - Mr. Au has experience as a director and officer of public companies in a wide range of industries since 2006. He has been involved in restructuring public companies and in various corporate transactions. Prior to that, he worked in the wealth management division of a major chartered bank in Canada where Mr. Au gained extensive experience managing portfolios for high net worth clients.

***Ljiljana Vujotic, Director*** - Prof. Vujotic has more than 30 years' experience as a clinician and specialist in the field of neurosurgery, currently as head of the Pediatric Neurosurgery Department, Clinical Center of the Serbia Neurosurgery Division in Belgrade, Serbia, in addition to serving as President of the NT Committee of Quality Improvement of Health Care in Serbia since 2004. Prof. Vujotic is also director of post-graduate studies and an experienced professor of Neurosurgery at the medical school at the University of Belgrade.

***Paolo De Luca, Director*** – Mr. De Luca has more than 20 years of diversified financial business experience, holding senior financial, investor relations, and accounting leadership roles at companies

including West Face Capital, one of Canada's leading alternative asset management firms; Meridian LNG; Potash Ridge; C.A. Bancorp; and TD Securities. Mr. De Luca is a graduate of York University's Schulich School of Business.

### **Audit Committee Oversight**

Since the commencement of the Company's most recently completed financial year, there has not been a recommendation of the Audit Committee to nominate or compensate an external auditor which was not adopted by the Board.

### **Reliance on Exemptions in NI 52-110 regarding**

#### ***De Minimis* Non-audit Services or on a Regulatory Order Generally**

Since the commencement of the Company's most recently completed financial year, the Company has not relied on:

1. the exemption in section 2.4 (*De Minimis Non-audit Services*) of NI 52-110 (which exempts all non-audit services provided by the Company's auditor from the requirement to be pre-approved by the Audit Committee if such services are less than 5% of the auditor's annual fees charged to the Company, are not recognized as non-audit services at the time of the engagement of the auditor to perform them and are subsequently approved by the Audit Committee prior to the completion of that year's audit); or
2. an exemption from the requirements of NI 52-110, in whole or in part, granted by a securities regulator under Part 8 (*Exemptions*) of NI 52-110.

### **Pre-Approval Policies and Procedures**

The Audit Committee has adopted specific policies and procedures for the engagement of non-audit services as described in the Charter.

### **Audit Fees**

The following table provides details in respect of audit, audit related, tax and other fees billed by the external auditor of the Company for professional services rendered to the Company during the fiscal years ended June 30, 2018 and June 30, 2017:

	<b>Audit Fees (\$)</b>	<b>Audit-Related Fees (\$)</b>	<b>Tax Fees (\$)</b>	<b>All Other Fees (\$)</b>
<b>Year ended June 30, 2018</b>	10,500	2,000	Nil	Nil
<b>Year ended June 30, 2017</b>	Nil	Nil	Nil	Nil

Audit Fees - aggregate fees billed for professional services rendered by the auditor for the audit of the Company's annual consolidated financial statements as well as services provided in connection with statutory and regulatory filings.

Audit-Related Fees - aggregate fees billed for professional services rendered by the auditor and were comprised primarily of audit procedures performed related to the review of quarterly financial statements and related documents.

Tax Fees - aggregate fees billed for tax compliance, tax advice and tax planning professional services. These services included reviewing tax returns and assisting in responses to government tax authorities.

All Other Fees - aggregate fees billed for professional services which included accounting advice and advice related to relocating employees.

## **REPORT ON GOVERNANCE**

The Company believes that adopting and maintaining appropriate governance practices is fundamental to a well-run company, to the execution of its chosen strategies and to its successful business and financial performance. National Instrument 58-101 – *Disclosure of Corporate Governance Practices* and National Policy 58-201 – *Corporate Governance Guidelines* (collectively the “**Governance Guidelines**”) of the Canadian Securities Administrators set out a list of non-binding corporate governance guidelines that issuers are encouraged to follow in developing their own corporate governance guidelines. In certain cases, the Company's practices comply with the guidelines, however, the Board considers that some of the guidelines are not suitable for the Company at its current stage of development and therefore these guidelines have not been adopted. The Company will continue to review and implement corporate governance guidelines as the business of the Company progresses and becomes more active in operations.

The following disclosure is required by the Governance Guidelines and describes the Company's approach to governance and outlines the various procedures, policies and practices that the Company and the Board have implemented.

### **Board of Directors**

Form 58-101F2 – *Corporate Governance Disclosure (Venture Issuers)* (“**Form 58-101F2**”) requires disclosure regarding how the Board facilitates its exercise of independent supervision over management of the Company by providing the identity of directors who are independent and the identity of directors who are not independent and the basis for that determination. NI 52-110 provides that a director is independent if he or she has no direct or indirect “material relationship” with the company. “Material relationship” is defined as a relationship which could, in the view of the Board, be reasonably expected to interfere with the exercise of a director's independent judgment. In addition, under NI 52-110, an individual who is, or has been within the last three years, an employee or executive officer of an issuer, is deemed to have a “material relationship” with the issuer.

The Board believes that it functions independently of management, and reviews its procedures on an ongoing basis to ensure that it is functioning independently of management. The Board meets without management present, as circumstances require. When conflicts arise, interested parties are precluded from voting on matters in which they may have an interest. In light of the suggestions contained in the Governance Guidelines, the Board convenes meetings, as deemed necessary, of the independent directors, at which non-independent directors and members of management are not in attendance.

Following the Meeting, it is expected that the Board will be comprised of four directors being Avram Adizes, Sydney Au, Ljiljana Vujotic, and Paolo De Luca. Mr. De Luca and is independent within the meaning of NI 52-110. Avram Adizes, the Chief Executive Officer, and Sydney Au, the Chief Financial Officer, are not independent as they are each executive officers of the Company and Prof. Vujotic has received more than \$75,000 in direct compensation from the Company during the last twelve month

period, and therefore those directors have a “material relationship” with the Company. In assessing Form 58-101F2 and making the foregoing determinations, the Board has examined the circumstances of each director in relation to a number of factors.

### **Directorships**

The following table sets forth the proposed directors of the Company who currently hold directorships with other reporting issuers:

<b>Name of Director</b>	<b>Reporting Issuer</b>
Avram Adizes	None
Sydney Au	Evitrade Health Systems Corp.
Ljiljana Vujotic	None
Paolo De Luca	None

### **Orientation and Continuing Education**

The Board does not have a formal orientation or education program for its members. The Board's continuing education is typically derived from correspondence with the Company's legal counsel to remain up to date with developments in relevant corporate and securities law matters. Additionally, historically Board members have been nominated who are familiar with the Company and the nature of its business.

### **Ethical Business Conduct**

The Board has not adopted guidelines or attempted to quantify or stipulate steps to encourage and promote a culture of ethical business conduct, but does promote ethical business conduct through the nomination of Board members it considers ethical, through avoiding or minimizing conflicts of interest, and by having at least two of its Board members independent of corporate matters.

### **Nomination of Directors**

The recruitment of new directors has generally resulted from recommendations made by directors and shareholders. The assessment of the contributions of individual directors has principally been the responsibility of the Board. Prior to standing for election, new nominees to the Board are reviewed by the entire Board.

### **Compensation**

The Board reviews the compensation of the directors and senior officers. The Board also makes determinations regarding the granting of Options to directors and senior officers, compensation for senior officers, and compensation for senior officers' and directors' fees, if any, from time to time. Senior officers and directors may be compensated in cash and/or equity for their expert advice and contribution towards the success of the Company. The form and amount of cash compensation will be evaluated by the Board, which will be guided by the following goals:

- compensation should be commensurate with the time spent by senior officers and directors in meeting their obligations and reflective of the compensation paid by companies similar to the Company in size, business and stage of development; and
- the structure of the compensation should be simple, transparent and easy for shareholders to understand. Shareholders will be given the opportunity to vote on all new or substantially revised equity compensation plans for directors as required by regulatory policies.

### **Other Board Committees**

The Board has no standing committees other than the Audit Committee.

### **Assessments**

The Board does not consider formal assessments useful given the stage of the Company's business and operations. However, the chairman of the Board meets annually with each director individually, which facilitates a discussion of his contribution and that of other directors. When needed, time is set aside at a meeting of the Board for a discussion regarding the effectiveness of the Board and its committees. If appropriate, the Board then considers procedural or substantive changes to increase the effectiveness of the Board and its committees. On an informal basis, the chairman of the Board is also responsible for reporting to the Board on areas where improvements can be made. A more formal assessment process will be instituted as, if, and when the Board considers it to be necessary.

### **OTHER MATTERS**

The management of the Company knows of no other matters to come before the Meeting other than as set forth in the Notice. However, if other matters which are not known to management should properly come before the Meeting, the accompanying form of proxy will be voted on such matters in accordance with the best judgment of the person or persons voting the proxy.

### **ADDITIONAL INFORMATION**

Additional information relating to the Company is available on SEDAR at [www.sedar.com](http://www.sedar.com).

Shareholders may contact the Company in order to request copies of: (i) this Circular; and (ii) the Company's consolidated financial statements and the related management's discussion and analysis (the "MD&A") which will be sent to the shareholder without charge upon request. Financial information is provided in the Company's consolidated financial statements and MD&A for its financial year ended June 30, 2018.

## **APPROVAL OF THE BOARD OF DIRECTORS**

The contents of this Circular have been approved, and the delivery of it to each shareholder entitled thereto and to the appropriate regulatory agencies has been authorized by the Board.

**DATED** at Vancouver, British Columbia, on the 14<sup>th</sup> day of November, 2018.

**BY ORDER OF THE BOARD**

*“Sydney Au” (signed)*

Chief Financial Officer and Director

## APPENDIX “A”

### EVIANA HEALTH CORPORATION (the “Corporation”)

#### AUDIT COMMITTEE CHARTER

This Charter establishes the composition, the authority, roles and responsibilities and the general objectives of the Corporation’s audit committee, or its Board of Directors (the “**Board**”) in lieu thereof (the “**Audit Committee**”). The roles and responsibilities described in this Charter must at all times be exercised in compliance with the legislation and regulations governing the Corporation and any subsidiaries.

#### 1. Composition

- (a) *Number of Members.* The Audit Committee must be comprised of a minimum of three directors of the Corporation, at least half of whom will be independent. Independence of the board members will be as defined by applicable legislation.
- (b) *Chair.* Audit Committee members will appoint a chair of the Audit Committee (the “**Chair**”) to serve for a term of one (1) year on an annual basis. The Chair may serve as the chair of the Audit Committee for any number of consecutive terms.
- (c) *Financially Literacy.* All members of the audit committee will be financially literate as defined by applicable legislation. If upon appointment a member of the Audit Committee is not financially literate as required, the person will be provided with a period of three months to acquire the required level of financial literacy.

#### 2. Meetings

- (a) *Quorum.* The quorum required to constitute a meeting of the Audit Committee is set at a majority of members.
- (b) *Agenda.* The Chair will set the agenda for each meeting, after consulting with management and the external auditor. Agenda materials such as draft financial statements must be circulated to all Audit Committee members for members to have a reasonable amount of time to review the materials prior to the meeting.
- (c) *Notice to Auditors.* The Corporation’s auditors (the “**Auditors**”) will be provided with notice as necessary of any Audit Committee meeting, will be invited to attend each such meeting and will receive an opportunity to be heard at those meetings on matters related to the Auditor’s duties.
- (d) *Minutes.* Minutes of the Audit Committee meetings will be accurately recorded, with such minutes recording the decisions reached by the committee.

#### 3. Roles and Responsibilities

The roles and responsibilities of the Audit Committee include the following:

##### External Auditor

The Audit Committee will:

- (a) *Selection of the external auditor.* Select, evaluate and recommend to the Board, for shareholder approval, the Auditor to examine the Corporation's accounts, controls and financial statements.
- (b) *Scope of Work.* Evaluate, prior to the annual audit by the Auditors, the scope and general extent of the Auditor's review, including the Auditor's engagement letter.
- (c) *Compensation.* Recommend to the Board the compensation to be paid to the external auditors.
- (d) *Replacement of Auditor.* If necessary, recommend the replacement of the Auditor to the Board.
- (e) *Approve Non-Audit Related Services.* Pre-approve all non-audit services to be provided by the Auditor to the Corporation or its subsidiaries.
- (f) *Direct Responsibility for Overseeing Work of Auditors.* Must directly oversee the work of the Auditor. The Auditor must report directly to the Audit Committee.
- (g) *Resolution of Disputes.* Assist with resolving any disputes between the Corporation's management and the Auditors regarding financial reporting.

#### Consolidated Financial Statements and Financial Information

The Audit Committee will:

- (a) *Review Audited Financial Statements.* Review the audited consolidated financial statements of the Corporation, discuss those statements with management and with the Auditor, and recommend their approval to the Board.
- (b) *Review of Interim Financial Statements.* Review and discuss with management the quarterly consolidated financial statements, and if appropriate, recommend their approval by the Board.
- (c) *MD&A, Annual and Interim Earnings Press Releases, Audit Committee Reports.* Review the Corporation's management discussion and analysis, interim and annual press releases, and audit committee reports before the Corporation publicly discloses this information.
- (d) *Auditor Reports and Recommendations.* Review and consider any significant reports and recommendations issued by the Auditor, together with management's response, and the extent to which recommendations made by the Auditor have been implemented.

#### Risk Management, Internal Controls and Information Systems

The Audit Committee will:

- (a) *Internal Control.* Review with the Auditors and with management, the general policies and procedures used by the Corporation with respect to internal accounting and financial controls. Remain informed, through communications with the Auditor, of any weaknesses in internal control that could cause errors or deficiencies in financial reporting or deviations from the accounting policies of the Corporation or from applicable laws or regulations.
- (b) *Financial Management.* Periodically review the team in place to carry out financial reporting functions, circumstances surrounding the departure of any officers in charge of financial reporting, and the appointment of individuals in these functions.
- (c) *Accounting Policies and Practices.* Review management plans regarding any changes in accounting practices or policies and the financial impact thereof.

- (d) *Litigation.* Review with the Auditors and legal counsel any litigation, claim or contingency, including tax assessments, that could have a material effect upon the financial position of the Corporation and the manner in which these matters are being disclosed in the consolidated financial statements.
- (e) *Other.* Discuss with management and the Auditors correspondence with regulators, employee complaints, or published reports that raise material issues regarding the Corporation's financial statements or disclosure.

### Complaints

- (a) *Accounting, Auditing and Internal Control Complaints.* The Audit Committee must establish a procedure for the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal controls or auditing matters.
- (b) *Employee Complaints.* The Audit Committee must establish a procedure for the confidential transmittal on condition of anonymity by the Corporation's employees of concerns regarding questionable accounting or auditing matters.

### **4. Authority**

- (a) *Auditor.* The Auditor, and any internal auditors hired by the Corporation, will report directly to the Audit Committee.
- (b) *To Retain Independent Advisors.* The Audit Committee may, at the Corporation's expense and without the approval of management, retain the services of independent legal counsels and any other advisors it deems necessary to carry out its duties and set and pay the monetary compensation of these individuals.

### **5. Reporting**

The Audit Committee will report to the Board on:

- (a) the Auditor's independence;
- (b) the performance of the Auditor and any recommendations of the Audit Committee in relation thereto;
- (c) the reappointment and termination of the Auditor;
- (d) the adequacy of the Corporation's internal controls and disclosure controls;
- (e) the Audit Committee's review of the annual and interim consolidated financial statements;
- (f) the Audit Committee's review of the annual and interim management discussion and analysis;
- (g) the Corporation's compliance with legal and regulatory matters to the extent they affect the financial statements of the Corporation; and
- (h) all other material matters dealt with by the Audit Committee.

**APPENDIX "B"**

**CHANGE OF AUDITOR REPORTING PACKAGE**

# **Eviana Health Corporation**

5728 E. Boulevard  
Vancouver, British Columbia  
V6M 4M4

**(The "Company")**

## **NOTICE OF CHANGE OF AUDITOR**

**(The "Notice")**

TO: British Columbia Securities Commission  
Alberta Securities Commission  
Ontario Securities Commission  
Adam Sung Kim Ltd., Chartered Accountant  
BDO Canada LLP

1. The directors of the Company do not propose to re-appoint Adam Sung Kim Ltd., Chartered Accountant, as auditors for the Company; and
2. The directors of the Company propose to appoint BDO Canada LLP, as the auditors of the Company, effective October 23, 2018 to hold office until the next annual meeting of the Company. BDO Canada LLP was engaged on August 16, 2018 and began its preliminary due diligence of the Company pending their succession as auditors of the Company upon Adam Sung Kim Ltd.'s resignation.

In accordance with National Instrument 51-102 *Continuous Disclosure Obligations* ("NI 51-102"), the Company confirms that:

1. Adam Sung Kim Ltd., Chartered Accountant was asked to resign as auditor of the Company, effective October 23, 2018 to facilitate the appointment of BDO Canada LLP of Vancouver, BC;
2. Adam Sung Kim Ltd., Chartered Accountant has not expressed any reservation nor any adverse opinion or disclaimer of opinion or an opinion qualified or modified as to uncertainty, audit scope or accounting principles in its reports for the most recently completed fiscal year of the Company, nor for the period from the most recently completed period for which Adam Sung Kim Ltd., Chartered Accountant issued an audit report in respect of the Company and the date of this Notice;
3. In the opinion of the Board of Directors of the Company, no "reportable event" as defined in NI 51-102 has occurred in connection with the audit of the most recently completed fiscal year of the Company nor any period from the most recently completed for which Adam Sung Kim Ltd., Chartered Accountant issued an audit report in respect of the Company and the date of this Notice; and
4. This Notice and Auditor's letters have been reviewed by the Audit Committee and the Board of Directors, and the decision to change auditors and the appointment of BDO Canada LLP, to the position of auditor was approved by the Audit Committee and the Board of Directors of the Company.

Dated as of the October 23, 2018.

**Eviana Health Corporation**

signed "Sydney Au"  
Sydney Au, Chief Financial Officer

UNIT 114B (2<sup>nd</sup> floor)  
8988 FRASERTON COURT  
BURNABY, BC, V5J 5H8

T: 604.318.5465  
F: 604.239.0866

**Adam Kim**

ADAM SUNG KIM LTD.  
CHARTERED PROFESSIONAL ACCOUNTANT

October 23, 2018

British Columbia Securities Commission  
Alberta Securities Commission  
Ontario Securities Commission

Dear Sirs/Mesdames:

**Re: Eviana Health Corporation (the “Company”)**  
**Notice of Change of Auditor Pursuant to National Instrument 51-102**

We have read the statements made by the Company in its Notice of Change of Auditor dated October 23, 2018 (the “**Notice**”), which we understand will be filed pursuant to Section 4.11 of National Instrument 51-102. We agree with the statements set out in the Notice, though we advise that we have no basis to agree or disagree with the comments in the Notice relating to BDO Canada LLP, Chartered Professional Accountants.

Yours truly,

**Adam Sung Kim Ltd., Chartered Professional Accountant**



---

Adam Joo Sung Kim, CPA, CA



Tel: 604 688 5421  
Fax: 604 688 5132  
www.bdo.ca

BDO Canada LLP  
600 Cathedral Place  
925 West Georgia Street  
Vancouver BC V6C 3L2 Canada

October 23, 2018

British Columbia Securities Commission  
Alberta Securities Commission  
Ontario Securities Commission

Dear Sirs:

Re: Eviana Health Corporation (the "Company")

As required under subparagraph (6)(a)(ii) of section 4.11 of National Instrument 51-102, we have read the Company's Change of Auditor Notice dated October 23, 2018 ("the Notice").

We confirm our agreement with the information contained in the Notice pertaining to our firm.

Yours very truly,

(signed) "BDO CANADA LLP"

Chartered Professional Accountants